Author's note: I present and update my best small-cap Busted IPO stock ideas only to subscribers of my exclusive marketplace, The Busted IPO Forum . Try a free 2-week trial today by clicking HERE .Shares of immunotherapy and vaccine concern ImmunityBio, Inc. (NASDAQ: IBRX ) are down nearly two-thirds over the past 18 months as cash needs forced dilution to the tune of 37%. Its IL-15 super-agonist fusion protein Anktiva isThe Busted IPO Forum is an investing group led by Bret Jensen, Chief Investment Strateg ...

Author's note: I present and update my best small-cap Busted IPO stock ideas only to subscribers of my exclusive marketplace, The Busted IPO Forum . Try a free 2-week trial today by clicking HERE .Shares of immunotherapy and vaccine concern ImmunityBio, Inc. (NASDAQ: IBRX ) are down nearly two-thirds over the past 18 months as cash needs forced dilution to the tune of 37%. Its IL-15 super-agonist fusion protein Anktiva isThe Busted IPO Forum is an investing group led by Bret Jensen, Chief Investment Strateg ...

Group 1 - The article promotes a weekly newsletter focused on stocks in the biotech, pharma, and healthcare industries, aimed at both novice and experienced investors [1] - The newsletter provides insights on key trends, catalysts driving valuations, product sales forecasts, and integrated financial statements for major pharmaceutical companies [1] - The author, Edmund Ingham, has over 5 years of experience in the biotech sector and has compiled detailed reports on more than 1,000 companies [1]

分组1 - ImmunityBio, Inc. (NASDAQ: IBRX) received a Refusal to File (RTF) letter from the FDA regarding its supplemental Biologics License Application (sBLA) for Anktiva in combination with BCG for BCG-unresponsive non-muscle invasive bladder cancer [1] - The RTF letter indicates that the FDA found issues with the submission that need to be addressed before the application can be considered [1] - This development may impact the company's stock performance and investor sentiment in the biotech sector [1]